Nasdaq FDA - Search News

FDA Approves 1st Non-Opioid Pain Drug in 20 Years

FDA approves Vertex's first-in-class non-opioid analgesic for acute pain

Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new drug is a non-opioid analgesic,

Hosted on MSN · 2h

Vertex gets FDA approval for non-opioid pain reliever

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) rose 3% in post-market trading Thursday on news the company had received FDA approval for its non-opioid pain reliever Journavx, also known as suzetrigine.

Eagle-Tribune · 3h

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain.

Axsome, FDA and migraine

Hosted on MSN · 4h

Axsome gets FDA approval for Symbravo for migraine

Axsome Therapeutics (NASDAQ:AXSM) has received FDA approval for its drug Symbravo for the acute treatment of migraine with or without aura in adults. Symbravo, a combination of meloxicam and rizatriptan,

Reuters on MSN · 2h

US FDA approves Axsome Therapeutics' migraine drug

The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday. The oral drug, branded Symbravo, was approved for the acute treatment of the condition characterized by recurrent attacks of moderate to severe throbbing and pulsating pain on one side of the head.

Business Insider · 5h

Axsome Therapeutics announces FDA approval of Symbravo

Axsome Therapeutics (AXSM) announced that the U.S. FDA has approved Symbravo for the acute treatment of migraine with or without aura in

Nasdaq2d

FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...

3hon MSN

Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025

We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...

GlobalData on MSN8h

Beta Bionics raises $204m to kickstart medtech IPO season

Beta Bionics has begun life as a public company with a $204m initial public offering (IPO), significantly higher than its anticipated target. The US-based company sold 12 million shares of its common ...

Nasdaq3d

Alvotech: FDA To Review BLA For AVT05 - Quick Facts

The FDA review process is anticipated to be completed ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

7hon MSN

Chimerix stock soars to 52-week high, hits $4.22

Chimerix Inc (NASDAQ: NASDAQ:CMRX) stock has reached a new 52-week high, touching $4.22 in recent trading, giving the company a market capitalization of $375 million. According to InvestingPro data, ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results